Celimax Surpasses 170 Billion Won in Annual Sales, Emerging as a Global Dermacosmetic Leader View original image

Dermacosmetic brand celimax has surpassed annual sales of 170 billion won, continuing its rapid growth trajectory.


After recording sales of 46.2 billion won in 2024, celimax achieved results approximately 3.7 times higher within just one year. Compared to its 2022 sales of 17.2 billion won, this represents nearly tenfold growth in three years.


Recent quarterly sales have also approached 70 billion won. When annualized, this corresponds to sales of over 270 billion won. Building on this growth momentum, global market expansion, and the strong performance of its core product lines, celimax has set its next growth target at achieving 400 billion won in sales by 2026.


Celimax's growth is based on ultra-fast expansion in both the domestic and global markets. In Korea, the brand has produced the top toner pad on Coupang, while internationally, it has launched the top retinal product on Amazon, proving the competitiveness of its key products. Recently, celimax has accelerated its expansion into the North American market by launching simultaneously in all 1,300 stores of Ulta Beauty, often referred to as the "Olive Young of the United States." This expansion in distribution is broadening consumer touchpoints around its core products, leading to positive trends in both sales growth and brand awareness.


If celimax achieves annual sales of 400 billion won in the future, it is likely to become one of the leading K-beauty indie brands. Considering the speed of its short-term growth and its growing presence in the global market, expectations for the company's future are rising.



Kim Minseok, CEO of celimax, stated, "We will continue to pursue our goal of becoming a 'global steady seller' by creating products that consumers want to repurchase and a brand they can trust."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing